This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Post-Operative Sub-Tenon Kenalog in Glaucoma Filtering Surgery

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2007 by Stanford University.
Recruitment status was:  Recruiting
Information provided by:
Stanford University Identifier:
First received: October 11, 2005
Last updated: February 22, 2008
Last verified: August 2007
Determine efficacy of sub tenon kenalog injections for post-operative management of trabeculectomy procedures.

Condition Intervention
Glaucoma Drug: Triamcinolone injection, sub-tenon

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Post-Operative Sub-Tenon Kenalog in Glaucoma Filtering Surgery

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Intraocular pressure

Secondary Outcome Measures:
  • visual field progression, need for further surgery or medications

Estimated Enrollment: 200
Detailed Description:

Postoperative sub-Tenon Triamcinolone Acetonide in glaucoma filtering surgery

Objectives: Trabeculectomy is a surgical procedure designed to reduce internal eye pressure by draining fluid from within the eye to the sub-conjunctival (superficial eye lining) space. Scar formation from conjunctival and Tenon's capsule fibroblast proliferation represents the most common cause of failure of trabeculectomies. A number of drugs have been use to prevent failure of trabeculectomies from the scarring process including intraoperative mitomycin C (MMC) and preoperative Triamcinalone Acetonide (TA). Over the past several years, intraoperative MMC has become a preferred method of preventing scar formation. This study looks to determine in a prospective, double-blind, randomized method the long-term efficacy and safety of MMC with postoperative TA compared to the standard practice of intraoperative MMC with postoperative prednisolone acetate drops in preventing scar related failures of trabeculectomies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Inclusion Criteria:Trabeculectomy surgery patient, age 18 or older - Exclusion Criteria:Pregnant, nursing, age less than 18, known allergy to medication being studied
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00238563

United States, California
Santa Clara valley Medical Center Recruiting
San Jose, California, United States, 95128
Contact: Christopher J Engelman, MD    408-885-6770   
Stanford University School of Medicine Recruiting
Stanford, California, United States, 94305
Contact: Christopher J Engelman, MD    408-885-6770   
Principal Investigator: Christopher James Engelman         
Sponsors and Collaborators
Stanford University
  More Information Identifier: NCT00238563     History of Changes
Other Study ID Numbers: 7/8/05-21
Study First Received: October 11, 2005
Last Updated: February 22, 2008

Additional relevant MeSH terms:
Ocular Hypertension
Eye Diseases
Triamcinolone hexacetonide
Triamcinolone Acetonide
Triamcinolone diacetate
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Immunosuppressive Agents
Immunologic Factors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 21, 2017